This trial has been completed.

Condition newly diagnosed hormone positive clinical stage 1 or 2 breast cancer
Treatments tamoxifen, breast cancer surgery
Phase phase 2
Sponsor University of Utah
Start date August 2012
End date November 2016
Trial size 52 participants
Trial identifier NCT01614210, HCI57098


The purpose of the study is to see if tumors respond to endocrine therapy by taking a total of 21 doses of Tamoxifen before and after surgery. Tamoxifen is currently approved by the FDA (Food and Drug Administration) for use in the treatment of hormone positive breast cancer.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Endpoint classification efficacy study
Intervention model single group assignment
Masking open label
Primary purpose treatment
All patients enrolled in the study.
All patients will take tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after surgery.
breast cancer surgery
Breast cancer surgery

Primary Outcomes

Reduction in Ki67 expression in tumors
time frame: 36 months

Secondary Outcomes

Evaluate symptom patterns
time frame: 36 months
time frame: 36 months
Correlation between changes in Ki67 and symptoms
time frame: 36 months

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - Age > 18 years old - Diagnosed with hormone receptor positive invasive breast cancer (ER or PR or both >1%) by core needle biopsy - Clinical AJCC 7th edition Stage 1 or 2 - Candidate for surgical therapy - ECOG performance status 0,1, or 2 - No chemotherapy or endocrine therapy for breast cancer in last 5 years - Paraffin fixed core needle tissue block, or biopsy punch available for central analysis for proliferative markers - Not pregnant or lactating and practicing adequate birth control if premenopausal - Able and willing to provide informed consent Exclusion Criteria: - Prior personal history of uterine cancer - Prior personal history of stroke or DVT - Current therapy with strong CYP2D6 inhibitors The following medications should not be administered with tamoxifen (21 day treatment period) and will need to be stopped for the designated period of time prior to starting the study tamoxifen. No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage 0, I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years Fluoxetine - should be discontinued 30 days prior to starting tamoxifen Paroxetine - should be discontinued 5 days prior to starting tamoxifen Sertraline - should be discontinued 5 days prior to starting tamoxifen Bupropion - should be discontinued 5 days prior to starting tamoxifen - Concurrent coumarin-type anticoagulation therapy - Any other contraindications to tamoxifen therapy

Additional Information

Official title Preoperative Window of Endocrine Therapy Provides Information to Increase Compliance
Principal investigator Leigh Neumayer, MD
Description Patients who are eligible (newly diagnosed hormone positive clinical stage 1 or 2 breast cancer) will be approached about the study. If they sign informed consent a prescription for 21 doses of Tamoxifen will be provided. The patient's surgery will be scheduled at a time convenient for the patient and the surgeon. Once the surgery has been scheduled, a medication calendar will be completed that allows the patient to take tamoxifen for 7 days preoperatively with the 7th dose of tamoxifen to coincide with the day before surgery. The patient will continue to take tamoxifen for 2 weeks (14 days) after surgery. Patients will then proceed along normal treatment guidelines. For those needing chemotherapy or radiation therapy, we recommend the long term endocrine therapy start at the conclusion of chemo and/or radiation treatments. For those not going on to any additional therapy, the prescription for endocrine therapy will be written at the initial post-operative visit. Unstained slides from the formalin-fixed, paraffin-embedded tissue blocks from the patient's breast tissue from which the original diagnosis of breast cancer was made by H&E will be stained for Ki67. After endocrine therapy and subsequent resection, carcinoma will be confirmed by the participating pathologist on H&E, and Ki67 will be performed on unstained slides from a representative tissue block containing invasive carcinoma. The pathologist will circle a designated area of tumor on the H&E slide and both the H&E and immunostained (Ki67) slides will be scanned in a digital imaging device (Aperio XT Scanscope), which quantitatively analyzes the tumor designated by the pathologist with image analysis algorithms. The algorithm accurately detects regions of interest and distinguishes cells and sub-cellular objects within these target regions. It determines morphology and expression profiles per individual cell or cell compartment. For Ki67 analysis, a nuclear Immunohistochemistry (IHC) algorithm will be used.
Trial information was received from ClinicalTrials.gov and was last updated in November 2016.
Information provided to ClinicalTrials.gov by University of Utah.